Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation-Reference-Cited by-同舟云学术

Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation

Published:2019-12 Issue:12 Volume:9 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Yang George^ORCID,Mills Matthew,Kim Youngchul,Figura Nicholas B.,Doyle Catherine^ORCID,Oliver Daniel,Grass G. Daniel,Robinson Timothy,Chavez Julio,Kim Sungjune

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-019-0269-6.pdf

Reference15 articles.

1. Freedman, A. Follicular lymphoma: 2018 update on diagnosis and management. Am. J. Hematol. 93, 296–305 (2018).

2. Solal-Celigny, P. et al. Follicular lymphoma international prognostic index. Blood 104, 1258–1265 (2004).

3. van de Schans, S. A. et al. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann. Oncol. 20, 1697–1702 (2009).

4. Bachy, E. et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132, 49–58 (2018).

5. Pastore, A. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 16, 1111–1122 (2015).

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma;Blood Advances;2024-02-13

2. Oral follicular lymphoma: a clinicopathologic and molecular study;Journal of Hematopathology;2023-11-02

3. Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma;Investigational New Drugs;2023-08-12

4. Development of a new risk scoring system based on spleen involvement and the lymphocyte/monocyte ratio for follicular lymphoma patients;Leukemia Research;2022-12

5. Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models;Frontiers in Oncology;2022-01-10